Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

362 Reports from FirstWord

   
  • COPD [2017]

    ...Obstructive Lung Disease (GOLD) recommend LABA/LAMAs as first line therapy in symptomatic patients regardless of exacerbation risk, and KOLs agree. LABA/LAMA marketing companies set to benefit include AstraZeneca, Boehringer Ingelheim, GSK and Novartis, but which ... Read More

  • Market Access Impact (US) [RCC]

    ...are preventing oncologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand? ... Read More

  • Market Access Impact (EU5) [RCC]

    ...EU5. The brands that can find a way to eliminate them stand to make important share gains. Especially in the middle of the market, where competition is lively, and at the bottom of the market, ... Read More

  • Prostate Cancer [2016]: Bulletin #2

    ...[olaparib] and Clovis Oncology’s rucaparib) that are in Phase III development for men with metastatic castration-resistant prostate cancer (mCRPC). KOLs also provide their first insights on the IMbassador250 Phase III study that was initiated in ... Read More

  • How Payers Want to Work With Pharma

    ...approach to payer negotiations getting your message across? Too often pharma fails to provide the data and contracting innovation that will unlock the door to a deal. It can be better. Report Overview In How ... Read More

  • Ovarian Cancer [2017]

    ...Co.’s Zejula. How will AstraZeneca’s Lynparza fare in the rapidly growing PARP inhibitor market and will the newer therapies in this class prove their worth? Furthermore, a multitude of novel combinations are being evaluated in ... Read More

  • NPS+ (US) [Asthma/COPD]

    ...abundance of choice impacting brand loyalty? What do physicians think today about the leading brands? And are they talking positively or negatively about each to their peers? Brand marketers can find out everything they need ... Read More

  • NPS+ (EU5) [Asthma/COPD]

    ...of choice impacting brand loyalty? What do physicians really think about the leading brands? And are they talking positively or negatively about each to their peers? Brand marketers can find out everything they need to ... Read More

  • Medical Affairs Reputations (US) [HIV]

    ...job. In the past 6 months, only one of those teams reached out to more than 70% of the infectious disease specialists we surveyed. Survey respondents also had a lot to say about how teams ... Read More

  • Medical Affairs Reputations (EU5) [HIV]

    ...doing a better job. They identified specific medical affairs services where teams are not up to par, and recommended several ways teams can improve both the information they provide, and the way they provide it. ... Read More

  • Targeted Therapies in Asthma [2017]: Bulletin #1

    ...at the American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI 2017) which demonstrates that efficacy of mepolizumab (Nucala) is not affected by the presence of nasal polyps (which can be indicative of a ... Read More

  • Psoriasis [2016]: Bulletin #3

    ...pivotal Phase III studies reporting the efficacy and safety of guselkumab (anti-IL23 monoclonal antibody [mAb]) in the treatment of adults with moderate to severe plaque psoriasis; Sun Pharmaceutical announcing new data from two pivotal Phase ... Read More

  • Payer Insights: MS [2016]: Bulletin #3

    ...the impact of the launch delay of generic Copaxone 40mg/ml and potential steps that Teva could take to retain market share of its branded Copaxone; approaches to reimbursing Alkermes’ ALKS 8700 and opinions on ways ... Read More

  • Real World Data -- Meeting payer needs

    ...Payers with stretched budgets are still struggling to make the case for ‘big ticket’ drugs. Whereas pharma is keen to prove that higher cost drugs are justified and will ultimately save money. But are payers ... Read More

  • Biosimilars: US Payer Perspectives

    ...too slow? Not so, argue payers. While the number of biosimilar approvals in the US still lags behind Europe, a solid foundation continues to be laid by multiple key stakeholder groups. Successes have been seen ... Read More

  • Medical Affairs Reputations (US) [RCC]

    ...our survey of 100 medical oncologists. As part of list of suggested improvements, they identified at least 4 ways that teams for major renal cell carcinoma (RCC) treatments could do a better job of providing ... Read More

  • Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

    ...of new data at the American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI 2017) which demonstrates that efficacy of mepolizumab (Nucala) is not affected by the presence of nasal polyps (which can be ... Read More

  • Psoriasis: Update Bulletin [April 2017]

    ...two pivotal Phase III studies reporting the efficacy and safety of guselkumab (anti-IL23 monoclonal antibody [mAb]) in the treatment of adults with moderate to severe plaque psoriasis; Sun Pharmaceutical announcing new data from two pivotal ... Read More

  • The Future of Biobetters

    ...unmet clinical need and increasing revenues, investment in the biobetter pipeline has grown rapidly. Yet biobetter products need to bring some serious clinical and cost saving advantages if they are to get stakeholder support and ... Read More

  • Medical Affairs Reputations (EU5) [RCC]

    ...our survey of 150 medical oncologists. As part of list of suggested improvements, they identified at least 5 ways that teams for major renal cell carcinoma (RCC) treatments could do a better job of providing ... Read More

  • Rheumatoid Arthritis [2017]

    ...however, it now looks like Eli Lilly/Incyte’s Olumiant (baricitinib) is likely to be launched first. KOL’s weigh in on Olumiant’s safety and efficacy, as well as its chances to become the market leader in the ... Read More

  • Charting the Orphan Drug Development Pipeline

    ...$114 billion in 2016, with sales forecast to rise to $209 billion by 2022. Orphan drugs enjoy favourable regulatory pathways, satisfy unmet clinical need and often command significant prices. No wonder that research efforts have ... Read More

  • Market Access Impact (US) [HIV]

    ...decades. New market entrants continue to arrive – the most recent from Gilead – hoping to disrupt the status quo. But how are market barriers impacting prescribing choices, and what effect does that have on ... Read More

  • Market Access Impact (EU5) [HIV]

    ...New market entrants continue to arrive – the most recent from Gilead – hoping to disrupt the status quo. But how are market barriers impacting prescribing choices, and what effect does that have on market ... Read More

  • NPS+ (US) [PsO]

    ...we surveyed them about. There is hope, though, as at least one of those brands is poised for a massive market share gain—up to 1000%—if it can win over Detractors. Find out what’s driving your ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook